Disease-modifying therapies in Alzheimer's disease: How far have we come?

Drugs

Volumn 66, Issue 16, 2006, Pages 2075-2093

  Hüll, Michael ^a   Berger, Mathias ^a   Heneka, Michael ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; ASCORBIC ACID; ATORVASTATIN; CELECOXIB; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; DONEPEZIL; EPIANDROSTERONE; ESOMEPRAZOLE; ESTRADIOL; ESTROGEN; FLURBIPROFEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IBUTAMOREN; INDOMETACIN; LEUPRORELIN; MEMANTINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASTERONE; PREGNENOLONE; PROGESTERONE; ROFECOXIB; SELEGILINE; SIMVASTATIN; TOCOPHEROL; UBIQUINONE; UNINDEXED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; GONADORELIN; METALLOPROTEINASE; MONOAMINE OXIDASE INHIBITOR; NERVE GROWTH FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SECRETASE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVITY; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNIZATION; IN VIVO STUDY; NONHUMAN; PHARMACOEPIDEMIOLOGY; PROTEIN AGGREGATION; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME ACTIVATION; IMMUNOTHERAPY; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALIA;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; ENZYME ACTIVATION; ESTROGENS; EXCITATORY AMINO ACID ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOTHERAPY; MEMANTINE; METALLOENDOPEPTIDASES; MONOAMINE OXIDASE INHIBITORS; NERVE GROWTH FACTORS; PHARMACOEPIDEMIOLOGY; PPAR GAMMA; TAU PROTEINS;

EID: 33847711478     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666160-00004     Document Type: Article

References (156)

1. Fillit HM, O'Connell AW, Brown WM, et al. Barriers to drug discovery and development for Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16 Suppl. 1: S1-8
2. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 (9503): 2112-7
3. Bond J, Stave C, Sganga A, et al. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract Suppl 2005; (146): 8-14
4. Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 2005; 3 (1): 39-49
5. Ferris SH. Clinical trials in AD: are current formats and outcome measures adequate? Alzheimer Dis Assoc Disord 2002; 16 Suppl. 1: S13-17
6. Dickerson BC, Sperling RA. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2005; 2 (2): 348-60
7. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004; 1 (2): 213-25
8. Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20 (1): 6-15
9. McDermott MP, Hall WJ, Oakes D, et al. Design and analysis of two-period studies of potentially disease-modifying treatments. Control Clin Trials 2002; 23 (6): 635-49
10. Jack CR, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003; 60 (2): 253-60
11. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005; (2): CD003154
12. Birks J, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD001190
13. Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2004; (4): CD001747
14. Birks J, Grimley EJ, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000; (4): CD001191
15. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75 (5): 677-85
16. NICE. Press release 2006/048 Oct 18 [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Sep 29]
17. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49 (3): 279-88
18. Greig NH, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17 (3): 159-65
19. Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21 (7): 453-78
20. Bartorelli L, Giraldi C, Saccardo M, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005; 21 (11): 1809-18
21. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21 (8): 1317-27
22. Pirttila T, Wilcock G, Truyen L, et al. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004; 11 (11): 734-41
23. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998; 50 (1): 136-45
24. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363 (9427): 2105-15
25. National Library of Medicine. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Sep 29]
26. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23 (4): 159-69
27. Hull M, Lieb K, Fiebich BL. Anti-inflammatory drugs: a hope for Alzheimer's disease? Expert Opin Investig Drugs 2000; 9 (4): 671-83
28. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21 (3): 383-421
29. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev 2002; (2): CD003673
30. Dvir E, Friedman JE, Lee JY, et al. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{4-[1-(p- chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetamido]butanoyl} -sn-glycero-3-phosophatidylcho line], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J Pharmacol Exp Ther 2006; 318 (3): 1248-56
31. Imbimbo BP. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs 2004; 13 (11): 1469-81
32. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289 (21): 2819-26
33. Zanetti O, Bonomini C, Pasqualetti P, et al. Effects of ibuprofen on Alzheimer's disease cognitive progression: a randomized controlled trial [abstract]. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S366
34. Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005; 2 (3): 355-65
35. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414 (6860): 212-6
36. Takahashi Y, Hayashi I, Tominari Y, et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003; 278 (20): 18664-70
37. Zhou Y, Su Y, Li B, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003; 302 (5648): 1215-7
38. Shie FS, Montine KS, Breyer RM, et al. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol 2005; 15 (2): 134-8
39. Waschbisch A, Fiebich BL, Akundi RS, et al. Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem 2006; 96 (3): 680-93
40. Slawik H, Volk B, Fiebich B, et al. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat striatum. Neurochem Int 2004; 45 (5): 653-60
41. Kawano T, Anrather J, Zhou P, et al. Prostaglandin E(2) EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006; 12 (2): 225-9
42. Gasparini L, Ongini E, Wilcock D, et al. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev 2005; 48 (2): 400-8
43. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112 (3): 440-9
44. Gordon ML, Mirza N, Bauer L, et al. Intravenous pulse cyclophosphamide in Alzheimer's disease: results of a pilot dose finding study [abstract]. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S360
45. Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006; 138 (3): 1031-9
46. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289 (20): 2651-62
47. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283 (8): 1007-15
48. Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra low-dose transdermal estradiol on cognitive function: results of a randomized clinical trial [abstract]. Alzheimer's Dementia 2006; 2 (3 Suppl. 1): S360
49. National Institute on Aging. Alzheimer's disease: therapeutic potential of estrogen [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 21]
50. Maki PM. Hormone therapy and risk for dementia: where do we go from here? Gynecol Endocrinol 2004; 19 (6): 354-9
51. Brinton RD. Impact of estrogen therapy on Alzheimer's disease: a fork in the road? CNS Drugs 2004; 18 (7): 405-22
52. Behl C. Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Subcell Biochem 2005; 38: 65-78
53. Weill-Engerer S, David JP, Sazdovitch V, et al. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab 2002; 87 (11): 5138-43
54. Hunter-Fleming Ltd. European study of HF0220 in mild to moderate Alzheimer's disease patients [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2006 Aug 17]
55. Gregory CW, Atwood CS, Smith MA, et al. Antigonadotropins: a novel strategy to halt Alzheimer's disease progression. Curr Pharm Des 2006; 12 (6): 685-90
56. LaPlante BJ, Powers CF, Gault JL, et al. Stabilization of cognitive decline in Alzheimer's disease following treatment with leuprolide acetate. Alzheimer's Dementia 2006; 2 (3 Suppl. 1): S620-1
57. Voyager Pharmaceuticals. ALADDIN Study phase III: Antigonadotropin- Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 20]
58. National Institute on Aging. SMART: Somatotrophins, Memory, and Aging Research Trial [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
59. Ryan JM, Ma GJ, Peng Y, et al. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of MK-0677 in slowing the progression of Alzheimer's disease [online]. Available from URL: http://www.alz.org/icad/abstracts.asp [Accessed 2006 Aug 21]
60. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62 (2): 217-24
61. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52 (3): 346-50
62. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62 (5): 753-7
63. National Institute on Aging. Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's disease study [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
64. Institute for the Study of Aging. Lipitor as a treatment for Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
65. Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol 2004; 15 (6): 667-72
66. Yrjanheikki J, Koistinaho J, Kettunen M, et al. Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. Brain Res 2005; 1052 (2): 174-9
67. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 2006; 185: 78-86
68. Butterfield DA, Howard BJ, LaFontaine MA. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr Med Chem 2001; 8 (7): 815-28
69. Luchsinger JA, Tang MX, Shea S, et al. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003; 60 (2): 203-8
70. Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother 2005; 39 (12): 2073-80
71. Salerno-Kennedy R, Cashman KD. Relationship between dementia and nutrition-related factors and disorders: an overview. Int J Vitam Nutr Res 2005; 75 (2): 83-95
72. Tabet N, Birks J, Grimley EJ. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 2000; (4): CD002854
73. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352 (23): 2379-88
74. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997 Apr 24; 336 (17): 1216-22
75. National Institute on Aging. Prevention of Alzheimer's Disease by VItamin E and SElenium (PREADVISE) [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2006 Aug 17]
76. Tucker JM, Townsend DM. Alpha-tocopherol: roles in prevention and therapy of human disease. Biomed Pharmacother 2005; 59 (7): 380-7
77. National Institute on Aging. Anti-oxidant treatment of Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
78. Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003; (1): CD000442
79. Youdim MB, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 2005; 126 (2): 317-26
80. Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL) -ethyl methyl carbamate]. Cell Mol Neurobiol 2001; 21 (6): 555-73
81. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437 (7057): 436-9
82. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 2003; 53 Suppl. 3: S87-97
83. Esai Medical Research Inc. Rasagiline 1mg and 2mg added to Arizept 10mg daily in patients with mild to moderate Alzheimer's disease (AD) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
84. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004; 45 (5): 583-95
85. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005; 2 (2): 155-65
86. McShane R, Areosa SA, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; 19; (2): CD003154
87. Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev 2002; (2): CD003153
88. Memory Pharmaceuticals. Safety and efficacy of MEM 1003 versus placebo in patients with mild to moderate Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
89. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002; (3): CD000147
90. Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002; 54 (12): 1567-77
91. ONO Pharma. Effects of ONO-2506PO in patients with Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
92. Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J 2006; 6 (1): 8-15
93. Tuszynski MH, Blesch A. Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease. Prog Brain Res 2004; 146: 441-9
94. Ramirez JJ, Parakh T, George MN, et al. The effects of neotrofin on septodentate sprouting after unilateral entorhinal cortex lesions in rats. Restor Neurol Neurosci 2002; 20 (1-2): 51-9
95. Apfel SC. Neurotrophic factor therapy: prospects and problems. Clin Chem Lab Med 2001; 39 (4): 351-5
96. Grundman M, Capparelli E, Kim HT, et al. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (neotrofin) in mild Alzheimer's disease patients. Life Sci 2003; 73 (5): 539-53
97. Sanofi-Aventis. Long-term safety extension with SR57667B in patients with Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
98. Sanofi-Aventis. Study of xaliproden (SR57746A) in patients with mild to moderate dementia of the Alzheimer's type [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
99. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11 (5): 551-5
100. Salehi A, Delcroix JD, Swaab DF. Alzheimer's disease and NGF signaling. J Neural Transm 2004; 111 (3): 323-45
101. Walter J, Kaether C, Steiner H, et al. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2001; 11 (5): 585-90
102. Ohyagi Y, Asahara H, Chui DH, et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J 2005; 19 (2): 255-7
103. Hardy J. Toward Alzheimer therapies based on genetic knowledge. Annu Rev Med 2004; 55: 15-25
104. Kohler C, Ebert U, Baumann K, et al. Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Neurobiol Dis 2005; 20 (2): 528-40
105. Gold G, Kovari E, Corte G, et al. Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease. J Neuropathol Exp Neurol 2001; 60 (10): 946-52
106. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286 (5440): 735-41
107. Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10 (12): 1317-24
108. Dewachter I, Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol 2002; 1 (7): 409-16
109. Garino C, Tomita T, Pietrancosta N, et al. Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors: design, synthesis, and enzymatic BACE-1 and cell assays. J Med Chem 2006; 49 (14): 4275-85
110. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5 (9): 677-85
111. Koo EH. The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic 2002; 3 (11): 763-70
112. Cao X, Sudhof TC. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem 2004; 279 (23): 24601-11
113. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398 (6727): 518-22
114. Washburn T, Schweighoffer E, Gridley T, et al. Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell 1997; 88 (6): 833-43
115. Pollack SJ, Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 2005; 6 (1): 35-47
116. Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76 (1): 173-81
117. Anderson JJ, Holtz G, Baskin PP, et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 2005; 69 (4): 689-98
118. Micchelli CA, Esler WP, Kimberly WT, et al. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy notch mutations in drosophila. FASEB J 2003; 17 (1): 79-81
119. Hartmann D, Tournoy J, Saftig P, et al. Implication of APP secretases in notch signaling. J Mol Neurosci 2001; 17 (2): 171-81
120. Lammich S, Okochi M, Takeda M, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem 2002; 277 (47): 44754-9
121. Kim DY, Ingano LA, Kovacs DM. Nectin-1alpha, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/gamma-secretase-like cleavage. J Biol Chem 2002; 277 (51): 49976-81
122. Marambaud P, Wen PH, Dutt A, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003; 114 (5): 635-45
123. May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem 2002; 277 (21): 18736-43
124. May P, Bock HH, Nimpf J, et al. Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. J Biol Chem 2003; 278 (39): 37386-92
125. Zou Z, Chung B, Nguyen T, et al. Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem 2004; 279 (33): 34302-10
126. Taniguchi Y, Kim SH, Sisodia SS. Presenilin-dependent 'gamma-secretase' processing of deleted in colorectal cancer (DCC). J Biol Chem 2003; 278 (33): 30425-8
127. Saura CA, Choi SY, Beglopoulos V, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004; 42 (1): 23-36
128. Tournoy J, Bossuyt X, Snellinx A, et al. Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice. Hum Mol Genet 2004; 13 (13): 1321-31
129. Rosen LB, Stone JA, Plump A, et al. The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S79
130. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006; 66 (4): 602-4
131. Effects of LY450139 dihydrate on subjects with mild to moderate Alzheimer's disease [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Aug 17]
132. Mintzer JE, Wilcock GK, Black SE, et al. MPC-7869 (R-furbiprofen), a selective Abeta42-lowering agent, delays time to clinically significant psychiatric events in Alzheimer's disease: analysis from a 12-month phase 2 trial. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S368
133. Wilcock GK, Black SE, Haworth J, et al. Efficacy and safety of MPC-7869 (R-flurbipofen), a selective Abeta42-lowering agent, in Alzheimer's disease: results of a 12 month phase 2 trial and a 1-year follow-on study. Alzheimers Dementia 2006; 2 (3 Suppl. 1): S81-2
134. Myriad Pharmaceuticals. Global efficcy study of MPC-7869 to treat patients with Alzheimer's [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2006 Aug 17]
135. Kojro E, Fahrenholz F. The non-amyloidogenic pathway: structure and function of alpha-secretases. Subcell Biochem 2005; 38: 105-27
136. Lichtenthaler SF, Haass C. Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. J Clin Invest 2004; 113 (10): 1384-7
137. Postina R, Schroeder A, Dewachter I, et al. A disintegrin- metalloproteinase prevents amyloid plaque formation and hip pocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004; 113 (10): 1456-64
138. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292 (5521): 1550-2
139. Yasojima K, McGeer EG, McGeer PL. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 2001; 919 (1): 115-21
140. Higuchi M, Iwata N, Saido TC. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim Biophys Acta 2005; 1751 (1): 60-7
141. Saito T, Iwata N, Tsubuki S, et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 2005; 11 (4): 434-9
142. Marr RA, Guan H, Rockenstein E, et al. Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci 2004; 22 (1-2): 5-11
143. Eckman EA, Watson M, Marlow L, et al. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003; 278 (4): 2081-4
144. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003; 100 (7): 4162-7
145. Yan P, Hu X, Song H, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006; 281 (34): 24566-74
146. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992; 359 (6393): 325-7
147. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992; 258 (5079): 126-9
148. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26: 267-98
149. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 1994; 91 (25): 12243-7
150. Pappolla M, Bozner P, Soto C, et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998; 273 (13): 7185-8
151. Gestwicki JE, Crabtree GR, Graef IA. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 2004; 306 (5697): 865-9
152. Gordon DJ, Sciarretta KL, Meredith SC. Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 2001; 40 (28): 8237-45
153. Sadowski M, Pankiewicz J, Scholtzova H, et al. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol 2004; 165 (3): 937-48
154. Adessi C, Frossard MJ, Boissard C, et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem 2003; 278 (16): 13905-11
155. Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors. CNS Drugs 2005; 19 (12): 989-96
156. Wright TM. Tramiprosate. Drugs Today (Barc) 2006; 42 (5): 291-8